MB
VERV

MPM BioImpact’s Verve Therapeutics VERV Stock Holding History

MPM BioImpact’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-638,163
Closed -$3.11M – 52
2024
Q2 		$3.11M Hold
638,163
– – 0.48% 43
2024
Q1 		$8.47M Hold
638,163
– – 1.36% 28
2023
Q4 		$8.9M Sell
638,163
-219,777
-26% -$2.72M 2.08% 23
2023
Q3 		$11.4M Hold
857,940
– – 3.04% 12
2023
Q2 		$16.1M Buy
857,940
+54,439
+7% +$907K 3.24% 11
2023
Q1 		$11.6M Sell
803,501
-5,160
-0.6% -$101K 3.01% 13
2022
Q4 		$15.6M Buy
808,661
+172,869
+27% +$4.58M 4.06% 9
2022
Q3 		$21.8M Buy
+635,792
New +$20.3M 5.17% 4

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

MPM BioImpact's VERV Position: Q3 2024 in Review

MPM BioImpact sold out of Verve Therapeutics (VERV) in Q3 2024, closing a stake of 638,163 shares — an estimated $3.11M sold.

MPM BioImpact first reported a position in VERV in Q3 2022 and held it in 8 quarters. The position peaked at $21.8M in Q3 2022. 174 funds tracked by Wall St. Rank hold VERV as of Q3 2024.

  • MPM BioImpact reported no remaining Verve Therapeutics position as of Q3 2024 after selling out during the quarter.
  • MPM BioImpact sold 638,163 Verve Therapeutics shares in Q3 2024, an estimated $3.11M.
  • MPM BioImpact first reported a position in Verve Therapeutics in Q3 2022 and held it in 8 quarters.
  • MPM BioImpact's Verve Therapeutics position peaked at $21.8M in Q3 2022.
  • 174 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2024.

Based on MPM BioImpact's 13F filing for Q3 2024, filed 13 Nov 2024.